2016

/
2016
Teacher Uses Puppetry and Filmmaking to Engage Students With Neurological Differences

Felt. Googly eyes. Socks. Pipe cleaners. Imagination. Sound familiar yet? Puppets! Patrick Waters, a teacher of special needs students, found that using these fun little…

CNN Announces Hero of The Year

Nobody’s perfect. We all have things about ourselves we wish we could change. For activist Jeison Aristizábal, having cerebral palsy, made life more challenging but he…

Life Happens at 3am

As soon as you become a mom life is no longer lived before bedtime. Pregnancy is the preparation for sleepless nights. That growing baby and…

Special Needs Athletes Have a Blast Playing With University Of Denver Lacrosse Team

When you think of being part of a team, what do you think of? Hard work? Effort? Commitment? Andrew Goodspeed joined a lacrosse team in…

Medikidz Explain Lennox-Gastaut Syndrome (LGS)

Eisai is pleased to announce the availability of the fifth comic book in the “Medikidz Explain Epilepsy” series, “Medikidz Explain Lennox-Gastaut Syndrome (LGS),” an educational comic…

CURE is now accepting LOIs for our first 2017 grant cycle.

NOW ACCEPTING APPLICATIONS CURE 2017 Cycle 1 Funding Opportunities CURE is now accepting LOIs for our first 2017 grant cycle. Innovator Award – $50,000 USD…

International Alliance for Pediatric Stroke (IAPS) News & World Stroke Day: October 29, 2016

Attention research teams: The NIH/NNHLBI recently announced a research project grant for perinatal stroke. This Funding Opportunity Announcement (FOA) solicits grant applications regarding basic or translational research…

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

London, UK; 26 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing…

Your Feedback Requested: Parents/Caregivers Medical Cannabis Survey

At the Child Neurology Foundation (CNF), our mission is to serve as a collaborative center of education and support for children living with neurologic conditions…

PCORI Annual Meeting Scholarships

The 2016 PCORI Annual Meeting is taking place in November in the greater Washington, D.C. area, and we’re offering scholarships to help patients, caregivers, and…

The Arc of Illinois Stipend Funds to Attend Conferences Related to Developmental Disability Issues

Consumer Stipend Funds The Arc of Illinois, through a grant from the Illinois Council on Developmental Disabilities, administers the Consumer Involvement Program and distributes consumer stipend…

The First Annual Luke G Neurological Scholarship from Bella Soul

Requirements for Scholarship: Must be a college student living with a neurological disorder. Must be enrolled as full time student. The limitations are not bound…

Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity and studied in patients with cerebral palsy Pivotal study in cerebral…

New Recommendations for Transitioning Youths with Brain Disorders to Adult Care

The Child Neurology Foundation (CNF) is pleased to announce the publication of a new consensus statement endorsed by the American Academy of Neurology (AAN), Child Neurology…

Enroll for Epilepsy Genetics Initiative today! Two new enrollment partners added

Enroll for Epilepsy Genetics Initiative today! Two new enrollment partners added EGI continues building upon the promise to tirelessly search for new ways of understanding the…

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

– Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo – – Today’s LGS data follows…

FYCOMPA® (perampanel) Oral Suspension Now Available as an Option for Patients with Epilepsy Who May Have Difficulty Swallowing Tablets or Prefer Liquids

Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty…

ANNOUNCING New CURE Program: Post-Traumatic Epilepsy Initiative

In collaboration with the U.S. Department of Defense, CURE is excited to launch a NEW research program to support a collaborative, milestone-driven approach to advance…

Partners Against Mortality in Epilepsy Conference

DATES: Thursday June 23 – Sunday, June 26 LOCATION: The Westin Alexandria, 400 Courthouse Square, Alexandria, VA 22314 CLOSEST AIRPORT: Reagan National (4.5 miles from…

Help Us Improve our Website: Parent, Caregiver, and Advocate Survey

In preparation for the upcoming Child Neurology Foundation (CNF) Board of Directors’ strategic planning meeting, we kindly request a few minutes of your time to complete…

  • 1
  • 2

Start typing and press Enter to search

Shopping Cart